1-benzhydryl-4-prop-2-enylpiperazine;hydron;dichloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-benzhydryl-4-prop-2-enylpiperazine;hydron;dichloride
• 化学式: C20H26Cl2N2
• 分子量: 365.3
• InChiKey: UEIVQDHTPHXDCD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.42
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  6.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  二苯甲基哌嗪 、 3-氯丙烯 生成 1-benzhydryl-4-prop-2-enylpiperazine;hydron;dichloride
  参考文献：
  名称：

  NINOV, KIRIL ASENOV;KARAKOLEV, PAVEL VASILEV;MITSEV, GEORGI KIRILOV;EVSTA+

  摘要：

  DOI：

文献信息

• NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES
  申请人：Lal Bansi

  公开号：US20110172425A1

  公开（公告）日：2011-07-14

  The present invention relates to a novel water based process for the preparation of substituted diphenylmethyl piperazines of Formula I and pharmaceutically acceptable salts wherein X 1 and X 2 represent independently a hydrogen, a halogen, a straight or branched chain lower alkyl, alkoxy or a hydroxyl radical and R is selected from groups such as acyl, alkyl, alkenyl, aralalkyl, aralalkenyl aralkyl, and aralalkenyl or aralkenyl hydroxyalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl or its derivative comprising, reacting a compound of Formula II, with a compound of formula R—X where R is as defined above and X is suitable leaving group which includes halides, but not limiting use of other leaving groups such as tosylate, mesylate and activated acid groups such as acyl halide, anhydrides, mixed anhydrides etc. using water as a solvent, in presence of a catalyst and a base, at 25-100° C.;

  本发明涉及一种用水为基础的新型过程，用于制备化合物I的取代二苯甲基哌嗪及其药用盐，其中X1和X2分别代表氢、卤素、直链或支链低碳基、烷氧基或羟基基团，R选自酰基、烷基、烯基、芳基烷基、芳基烯基、芳基、芳基烯基或芳基羟基烷基、芳基氧基烷基、烷氧基烷基、氨基烷基或其衍生物等，包括将化合物II与化合物R-X反应，其中R如上定义，X是适当的离去基团，包括卤素等卤素，但不限于其他离去基团，如对甲苯磺酸酯、甲磺酸酯和活化酸基团，如酰卤、酸酐、混合酸酐等，使用水作为溶剂，在催化剂和碱的存在下，在25-100°C条件下进行。
• Novel crystalline form of 1-benzhydryl-4-allylpiperazine dihydrochloride and method for the production thereof
  申请人：SO "PHARMACHIM"

  公开号：EP0189679A1

  公开（公告）日：1986-08-06

  A novel anhydrous crystalline form of 1-benzhydryl-4- allylpiperazine dihydrochloride which possesses absorption bands in its IR-spectra (tablets with nujol mulls) at 646 and 665 cm-1, a ratio A646/A661 = 0.6, a specific triplet at 915, 926 and 952 cm-1, a ratio A926/A952 = 0.8, absence of a band at 3380 cm-1 and a strongest X-ray diffraction band at 27.4 2θ, corresponding to 37.8 nm and good water solubility properties rendering it suitable for use in preparation for sterile injectable solutions is prepared by acidifying solutions of 1-benzhydryl-4-allylpiperazine in aqueous alcoholic media.

  一种新型无水结晶形式的 1-二苯甲酰基-4-烯丙基哌嗪二盐酸盐，在其红外光谱（含 nujol mulls 的片剂）中具有 646 和 665 cm-1 处的吸收带，比率 A646/A661 = 0.6，915、926 和 952 cm-1 处的特定三重，比率 A926/A952 = 0.8，没有 3380 cm-1 处的吸收带，以及 27.4 2θ 处最强的 X 射线衍射带，相当于 37.8 nm，具有良好的水溶性，使其适合用于生产。此外，1-二苯甲酰基-4-烯丙基哌嗪在水醇介质中的酸化溶液具有良好的水溶性，适合用于制备无菌注射液。
• METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER
  申请人：Haggerty Timothy J.

  公开号：US20140335050A1

  公开（公告）日：2014-11-13

  The invention features methods, compositions, and kits for the administration of an HSP90 inhibitor, OBAA, flunarizine, aphidicolin, damnacanthal, dantrolene, or an analog thereof, alone, or in combination with, e.g., a TAA, an antigen-binding scaffold (e.g., an antibody, a soluble T cell receptor, or a chimeric receptor) specific for a TAA, a cell (e.g., a white blood cell that targets a cancer cell), and/or an IFN-β receptor agonist or an IFN-γ receptor agonist, for the treatment of cancer.
• US3957790A
  申请人：——

  公开号：US3957790A

  公开（公告）日：1976-05-18
• [EN] NOVEL WATER BASED PROCESS FOR THE PREPARATION OF SUBSTITUTED DIPHENYLMETHYL PIPERAZINES<br/>[FR] NOUVEAU PROCÉDÉ AQUEUX POUR LA SYNTHÈSE DE DIPHÉNYLMÉTHYLPIPÉRAZINES SUBSTITUÉES
  申请人：CALYX CHEMICALS AND PHARMACEUT

  公开号：WO2010046908A2

  公开（公告）日：2010-04-29

  The present invention relates to a novel water based process for the preparation of substituted diphenylmethyl piperazines of Formula (I) and pharmaceutically acceptable salts: wherein X1 and X2 represent independently a hydrogen, a halogen, a straight or branched chain lower alkyl, alkoxy or a hydroxyl radical and R is selected from groups such as acyl, alkyl, alkenyl, aralalkyl, aralalkenyl aralkyl, and aralalkenyl or aralkenyl hydroxyalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl or its derivative comprising, reacting a compound of Formula (II), with a compound of formula R-X where R is as defined above and X is suitable leaving group which includes halides, but not limiting use of other leaving groups such as tosylate, mesylate and activated acid groups such as acyl halide, anhydrides, mixed anhydrides etc.using water as a solvent, in presence of a catalyst and a base, at 25-100 °C; Formula (II).